Ebola virus threatens magcates and increases the need for increase in vaccine stocks
The suspicion is that 300,000 doses of Ebola vaccine are sufficient to control the global crisis reserve future epidemic, because deadly disease reaches megatitis from rural forest areas.
In response to the World Health Organization (WHO) and GVI Vaccine Connection, experts are already talking to prominent producers of Ebola immune system Merck, to explain how big a global dose reserves should be.
"We are actively engaged with the Global Health Organization and try to understand groups such as GAVI, the US Government and other groups, what will be the proper reserve size in the future," said Betty, director of Merck's Clinical Research. -An caller, in telephone interview.
Supply of vaccine from Merck, which is currently being used to erupt in Ebola outbreak in the Democratic Republic of Congo, there is no problem at this time, Deputy Director General of Emergency Preparedness and Response of the WHO, Peter Salma.
But the nature of Ebola spread is changing, Salma told Reuters As the virus goes from rural villages to urbanized populations, plans for how to accommodate it in the future also need to be changed.
"I am worried that there is medium and long-term reserves. The number of 300,000 was mostly based on the spread of previous Ebola in which it did not have large number of cases because they were in separate and rural populations. But now, we are more and more Ebola in megacitias and towns Have watched, "he added.
"We need to see it as an urban and rural disease, and therefore a different order of intensity of preparation including vaccine is required," Salma said.
Experimental vaccine against Merco's Ebola, known as RVSV-zebovie, is the most advanced development. According to global health officials, Johnson and Johnson's other vaccine may eventually become part of the reserve.
Mercury vaccine in West Africa has been shown to be safe and effective in testing, but has not been approved by European and US regulators yet, so it is used to break Congo under special emergency regulations for experimental products.
When it receives approval, the caller expects to be in 2019, it will be carried out in Germany's manufacturing plant. The caller states that Merck is not yet clear how much dosage it can produce for one year, or one month, but emphasized that the company "will collaborate with the public health agencies to try their best to support their needs."